Opioid-induced constipation in chronic noncancer pain

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 23, Issue 1, 2016, Pages 11-17

  Weber, H Christian ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Constipation; Lubiprostone; Methylnaltrexone; Naloxegol; Noncancer pain; Opioid receptor antagonist; Opioid induced constipation

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; FATTY ACID; LAXATIVE; LUBIPROSTONE; NALOXEGOL; NALOXONE; OPIATE; PRUCALOPRIDE; CHLORIDE CHANNEL STIMULATING AGENT; MACROGOL DERIVATIVE; MORPHINAN DERIVATIVE; MU OPIATE RECEPTOR; NALTREXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; QUATERNARY AMMONIUM DERIVATIVE;

ADVERSE DRUG REACTION; ANALGESIA; CANCER PAIN; CHRONIC PAIN; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONSTIPATION; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; MANAGED CARE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OPIOID INDUCED CONSTIPATION; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT INDICATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED;

ANALGESICS, OPIOID; CHLORIDE CHANNEL AGONISTS; CHRONIC PAIN; CONSTIPATION; HUMANS; LUBIPROSTONE; MORPHINANS; NALTREXONE; NARCOTIC ANTAGONISTS; POLYETHYLENE GLYCOLS; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, OPIOID, MU;

EID: 84952314233     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000220     Document Type: Review

References (59)

1. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008; 11:S63-S88.
2. Thielke SM, Simoni-Wastila L, Edlund MJ, et al. Age and sex trends in longterm opioid use in two large American health systems between 2000 and 2005. Pain Med 2010; 11:248-256.
3. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic noncancer pain. Pharmacoepidemiol Drug Saf 2009; 18:1166-1175.
4. Xu Y, Johnson A. Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costs. Pain Res Treat 2013; 2013: 943014.
5. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic noncancer pain: a systematic review. J Pain Symptom Manage 2003; 26:1026-1048.
6. Dhalla IA, Persaud N, Juurlink DN. Facing up to the prescription opioid crisis. BMJ 2011; 343:d5142.
7. Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015; 372:241-248.
8. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010; CD006605.
9. Juurlink DN, Dhalla IA. Dependence and addiction during chronic opioid therapy. J Med Toxicol 2012; 8:393-399.
10. Dorn S, Lembo A, Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Am J Gastroenterol 2014; 2:31-37.
11. Ketwaroo GA, Cheng V, Lembo A. Opioid-induced bowel dysfunction. Curr Gastroenterol Rep 2013; 15:344.
12. Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012; 72:1847-1865.
13. Warner EA. Opioids for the treatment of chronic noncancer pain. Am J Med 2012; 125:1155-1161.
14. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182:11S-18S.
15. Camilleri M, Drossman DA, Becker G, et al. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil 2014; 26:1386-1395.
16. Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther 2008; 27:1224-1232.
17. Rauck RL. Treatment of opioid-induced constipation: focus on the peripheral mu-opioid receptor antagonist methylnaltrexone. Drugs 2013; 73:1297-1306.
18. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009; 10:35-42.
19. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag 2009; 5:137-144.
20. Diego L, Atayee R, Helmons P, et al. Novel opioid antagonists for opioidinduced bowel dysfunction. Expert Opin Investig Drugs 2011; 20:1047-1056.
21. Coyne KS, LoCasale RJ, Datto CJ, et al. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res 2014; 6:269-281.
22. Bader S, Durk T, Becker G. Methylnaltrexone for the treatment of opioid-induced constipation. Expert Rev Gastroenterol Hepatol 2013; 7:13-26.
23. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009; 155:11-17.
24. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011; 106:835-842.
25. Camilleri M. Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. J Clin Invest 2013; 123:4111-4120.
26. Galligan JJ, Akbarali HI. Molecular physiology of enteric opioid receptors. Am J Gastroenterol 2014; 2:17-21.
27. Holzer P. Pharmacology of opioids and their effects on gastrointestinal function. Am J Gastroenterol Suppl 2014; 2:9-16.
28. Sobczak M, Salaga M, Storr MA, Fichna J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol 2014; 49: 24-45.
29. Ishihara M, Ikesue H, Matsunaga H, et al. A multiinstitutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain 2012; 28:373-381.
30. Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011; CD003448.
31. Brenner DM, Chey WD. An evidence-based review of novel and emerging therapies for constipation in patients taking opioid analgesic. Am J Gastroenterol Suppl 2014; 2:38-46.
32. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioidinduced constipation in advanced illness. N Engl J Med 2008; 358:2332-2343.
33. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage 2007; 34:547-565.
34. McNicol E, Boyce DB, Schumann R, Carr D. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials. Pain Med 2008; 9:634-659.
35. Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014; 370:2387-2396.
36. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009; 7:39-46.
37. Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain 2011; 12:554-562.
38. Michna E, Weil AJ, Duerden M, et al. Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis. Pain Med 2011; 12:1223-1230.
39. Lubiprostone: RU 0211, SPI 0211. Drugs R D 2005; 6:245-248.
40. Cryer B, Katz S, Vallejo R, et al. A randomized study of lubiprostone for opioidinduced constipation in patients with chronic noncancer pain. Pain Med 2014; 15:1825-1834.
41. Jamal MM, Adams AB, Jansen JP, Webster LR. A randomized, placebocontrolled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol 2015; 110:725-732.
42. Rao S, Weber HC. New treatment targets for the management of irritable bowel syndrome. Curr Opin Endocrinol Diabetes Obes 2014; 21:9-14.
43. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and metaanalysis. Am J Gastroenterol 2013; 108:1566-1574.
44. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002; 23:48-53.
45. Chamberlain BH, Cross K, Winston JL, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage 2009; 38:683-690.
46. Nalamachu SR, Pergolizzi J, Taylor R Jr, et al. Efficacy and tolerability of subcutaneous methylnaltrexone in patients with advanced illness and opioidinduced constipation: a responder analysis of 2 randomized, placebo-controlled trials. Pain Pract 2015; 15:564-571.
47. Webster L, Chey WD, Tack J, et al. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther 2014; 40:771-779.
48. Naloxegol (Movantik) for opioid-induced constipation. Med Lett Drugs Ther 2015; 57:135-137.
49. Webster L, Dhar S, Eldon M, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 2013; 154:1542-1550.
50. McCarberg BH. Overview and treatment of opioid-induced constipation. Postgrad Med 2013; 125:7-17.
51. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290:G942-947.
52. Lubiprostone (amitiza) for chronic constipation. Med Lett Drugs Ther 2006; 48:47-48.
53. Lubiprostone (Amitiza) for irritable bowel syndrome with constipation. Med Lett Drugs Ther 2008; 50:53-54.
54. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007; 25:1351-1361.
55. Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 27:685-696.
56. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008; 103:170-177.
57. Spierings E, Joswick T, Lindner E, et al. Long-term safety and efficacy of lubiprostone in opioid-induced constipation in patients with chronic, noncancer pain: results from a phase 3, open-label clinical trial. Painweek 2013; 75.
58. Spierings E, Joswick T, Mareya S, et al. Lubiprostone for treatment of opioidinduced constipation does not interfere with opioid analgesic effects in patients with noncancer pain. Painweek 2013; 106.
59. Cuppoletti J, Chakrabarti J, Tewari K, Malinowska DH. Methadone but not morphine inhibits lubiprostone-stimulated Cl-currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl-currents. Cell Biochem Biophys 2013; 66:53-63.